Deerfield Management Company, L.P. (Series C) Nuvalent, Inc. Transaction History
Deerfield Management Company, L.P. (Series C)
- $5.37 Billion
- Q3 2025
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Nuvalent, Inc. stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 17,991,024 shares of NUVL stock, worth $1.74 Billion. This represents 28.96% of its overall portfolio holdings.
Number of Shares
17,991,024
Previous 17,991,024
-0.0%
Holding current value
$1.74 Billion
Previous $1.37 Billion
13.34%
% of portfolio
28.96%
Previous 31.57%
Shares
3 transactions
Others Institutions Holding NUVL
# of Institutions
210Shares Held
61.3MCall Options Held
35.1KPut Options Held
62.2K-
Paradigm Biocapital Advisors LP New York, NY5.27MShares$509 Million14.68% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.61MShares$444 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.02MShares$292 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA2.3MShares$222 Million0.04% of portfolio
-
Janus Henderson Group PLC London, X02.19MShares$211 Million0.09% of portfolio
About Nuvalent, Inc.
- Ticker NUVL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,977,800
- Market Cap $4.15B
- Description
- Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...